Pharmaceutical pricing in Croatia: a comparison of ordinances in 2013 versus 2009 and their potential savings to provide future guidance

Brian Godman, Hye-Young Kwon, Ljiljana Sović Brkičić , Martina Bogut , Miron Sršen , Tonko Tabain , Winnie de Bruyn

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Croatia has introduced a number of reforms to contain pharmaceutical expenditure whilst increasing access to new medicines. These include new regulations and new ordinances in 2013 including the pricing of new medicines and lowering the price of generics. Describe changes in the 2013 ordinance for new and established medicines in Croatia and the potential savings to provide future guidance. Methods: Descriptive review of the new ordinances for pricing and reimbursement of pharmaceuticals and calculations of potential savings from the various initiatives. There were changes in the ordinance for the pricing of new medicines in Croatia including the order of reference priced countries. There were also changes in the pricing of biosimilars as well as comparator levels with other countries. Projections show that with the new ordinance, ambulatory care expenditure for the 54 product groups (internal reference price system) will be reduced by 9.64% (318.4 million kunas) and prices of new medicines lowered by 8 to 10% following changes in the order of referenced price countries. This paper demonstrates that changes in the reference pricing system can lead to considerable differences in overall reimbursed expenditure. In addition, European countries with smaller populations can be active with introducing a variety of measures to keep pharmaceutical expenditure under control whilst increasing access to new medicines. Further reforms will be needed to improve the quality of prescribing. It is also likely further ordinances will be needed to keep pharmaceutical expenditure under control.
LanguageEnglish
Pages79-89
Number of pages11
JournalGenerics and Biosimilars Initiative journal
Volume4
Issue number2
Early online date11 May 2015
DOIs
Publication statusPublished - 2015

Fingerprint

Croatia
Health Expenditures
Medicine
Costs and Cost Analysis
Pharmaceutical Preparations
Costs
Biosimilar Pharmaceuticals
Drug Dosage Calculations
Ambulatory Care
Bioelectric potentials
Population

Keywords

  • biosmilars
  • reforms
  • reference pricing
  • pharmaceuticals
  • generics
  • Croatia

Cite this

Godman, Brian ; Kwon, Hye-Young ; Sović Brkičić , Ljiljana ; Bogut , Martina ; Sršen , Miron ; Tabain , Tonko ; de Bruyn, Winnie. / Pharmaceutical pricing in Croatia : a comparison of ordinances in 2013 versus 2009 and their potential savings to provide future guidance. In: Generics and Biosimilars Initiative journal. 2015 ; Vol. 4, No. 2. pp. 79-89.
@article{0a45e85f6e014f7798b705ede6901949,
title = "Pharmaceutical pricing in Croatia: a comparison of ordinances in 2013 versus 2009 and their potential savings to provide future guidance",
abstract = "Croatia has introduced a number of reforms to contain pharmaceutical expenditure whilst increasing access to new medicines. These include new regulations and new ordinances in 2013 including the pricing of new medicines and lowering the price of generics. Describe changes in the 2013 ordinance for new and established medicines in Croatia and the potential savings to provide future guidance. Methods: Descriptive review of the new ordinances for pricing and reimbursement of pharmaceuticals and calculations of potential savings from the various initiatives. There were changes in the ordinance for the pricing of new medicines in Croatia including the order of reference priced countries. There were also changes in the pricing of biosimilars as well as comparator levels with other countries. Projections show that with the new ordinance, ambulatory care expenditure for the 54 product groups (internal reference price system) will be reduced by 9.64{\%} (318.4 million kunas) and prices of new medicines lowered by 8 to 10{\%} following changes in the order of referenced price countries. This paper demonstrates that changes in the reference pricing system can lead to considerable differences in overall reimbursed expenditure. In addition, European countries with smaller populations can be active with introducing a variety of measures to keep pharmaceutical expenditure under control whilst increasing access to new medicines. Further reforms will be needed to improve the quality of prescribing. It is also likely further ordinances will be needed to keep pharmaceutical expenditure under control.",
keywords = "biosmilars, reforms, reference pricing, pharmaceuticals, generics, Croatia",
author = "Brian Godman and Hye-Young Kwon and {Sović Brkičić}, Ljiljana and Martina Bogut and Miron Sršen and Tonko Tabain and {de Bruyn}, Winnie",
year = "2015",
doi = "10.5639/gabij.2015.0402.017",
language = "English",
volume = "4",
pages = "79--89",
journal = "Generics and Biosimilars Initiative journal",
issn = "2033-6403",
number = "2",

}

Pharmaceutical pricing in Croatia : a comparison of ordinances in 2013 versus 2009 and their potential savings to provide future guidance. / Godman, Brian; Kwon, Hye-Young; Sović Brkičić , Ljiljana ; Bogut , Martina ; Sršen , Miron ; Tabain , Tonko ; de Bruyn, Winnie.

In: Generics and Biosimilars Initiative journal, Vol. 4, No. 2, 2015, p. 79-89.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pharmaceutical pricing in Croatia

T2 - Generics and Biosimilars Initiative journal

AU - Godman, Brian

AU - Kwon, Hye-Young

AU - Sović Brkičić , Ljiljana

AU - Bogut , Martina

AU - Sršen , Miron

AU - Tabain , Tonko

AU - de Bruyn, Winnie

PY - 2015

Y1 - 2015

N2 - Croatia has introduced a number of reforms to contain pharmaceutical expenditure whilst increasing access to new medicines. These include new regulations and new ordinances in 2013 including the pricing of new medicines and lowering the price of generics. Describe changes in the 2013 ordinance for new and established medicines in Croatia and the potential savings to provide future guidance. Methods: Descriptive review of the new ordinances for pricing and reimbursement of pharmaceuticals and calculations of potential savings from the various initiatives. There were changes in the ordinance for the pricing of new medicines in Croatia including the order of reference priced countries. There were also changes in the pricing of biosimilars as well as comparator levels with other countries. Projections show that with the new ordinance, ambulatory care expenditure for the 54 product groups (internal reference price system) will be reduced by 9.64% (318.4 million kunas) and prices of new medicines lowered by 8 to 10% following changes in the order of referenced price countries. This paper demonstrates that changes in the reference pricing system can lead to considerable differences in overall reimbursed expenditure. In addition, European countries with smaller populations can be active with introducing a variety of measures to keep pharmaceutical expenditure under control whilst increasing access to new medicines. Further reforms will be needed to improve the quality of prescribing. It is also likely further ordinances will be needed to keep pharmaceutical expenditure under control.

AB - Croatia has introduced a number of reforms to contain pharmaceutical expenditure whilst increasing access to new medicines. These include new regulations and new ordinances in 2013 including the pricing of new medicines and lowering the price of generics. Describe changes in the 2013 ordinance for new and established medicines in Croatia and the potential savings to provide future guidance. Methods: Descriptive review of the new ordinances for pricing and reimbursement of pharmaceuticals and calculations of potential savings from the various initiatives. There were changes in the ordinance for the pricing of new medicines in Croatia including the order of reference priced countries. There were also changes in the pricing of biosimilars as well as comparator levels with other countries. Projections show that with the new ordinance, ambulatory care expenditure for the 54 product groups (internal reference price system) will be reduced by 9.64% (318.4 million kunas) and prices of new medicines lowered by 8 to 10% following changes in the order of referenced price countries. This paper demonstrates that changes in the reference pricing system can lead to considerable differences in overall reimbursed expenditure. In addition, European countries with smaller populations can be active with introducing a variety of measures to keep pharmaceutical expenditure under control whilst increasing access to new medicines. Further reforms will be needed to improve the quality of prescribing. It is also likely further ordinances will be needed to keep pharmaceutical expenditure under control.

KW - biosmilars

KW - reforms

KW - reference pricing

KW - pharmaceuticals

KW - generics

KW - Croatia

UR - http://gabi-journal.net/pharmaceutical-pricing-in-croatia-a-comparison-of-ordinances-to-provide-future-guidance-especially-regarding-reference-pricing.html

U2 - 10.5639/gabij.2015.0402.017

DO - 10.5639/gabij.2015.0402.017

M3 - Article

VL - 4

SP - 79

EP - 89

JO - Generics and Biosimilars Initiative journal

JF - Generics and Biosimilars Initiative journal

SN - 2033-6403

IS - 2

ER -